Martin Kaiser: Co-occurrence of more than 2 HRCAs is associated with highest unmet need in NDMM and RRMM
Martin Kaiser, Reader in Molecular Haematology at The Institute of Cancer Research, shared an article on X:
“Very happy to see our global collaborative effort published in Journal of Clinical Oncology: co-occurrence of ≥2 HRCAs is consistently associated with highest unmet need in NDMM and RRMM, across time and treatment modalities.
This work took a federated analysis approach, letting all participating collaborators investigate themselves trial-by-trial how consistent co-occurrence of 2+ HRCAs is for predicting high-risk myeloma , using a centrally pre-defined free algorithm that was shared with everyone.
The results were highly consistent, which is striking, given the vastly heterogeneous treatments and patient populations.
Without a need for complex data transfers, scientists around the globe were empowered to interrogate their own data and explore new aspects across trials.
Prognostic association of 2+ HRCAs with poorer outcome was stronger for trials performed after 2015, suggesting marked progress for standard risk, less so for high-risk patients.
Fortunately, very recent GMMG-CONCEPT and OPTIMUM/MUKnine trials have informed better approaches.
A fantastic collaborative effort, very grateful to all, (Marc S. Raab, Marivi mateos, Bruno Paiva, Heidelberg Myeloma on this platform) and many other co-authors, their study groups and teams and, most of all, patients!
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.
Authors: Martin F. Kaiser, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023